Alberto García-Hernandez, T. Pérez, M. Pardo, D. Rizopoulos
{"title":"A flexible analytical framework for reference-based imputation, delta adjustment and tipping-point stress-testing","authors":"Alberto García-Hernandez, T. Pérez, M. Pardo, D. Rizopoulos","doi":"10.1080/19466315.2022.2151506","DOIUrl":null,"url":null,"abstract":"Abstract This article addresses the challenge of implementing the treatment policy strategy when subjects are not followed up after treatment discontinuation. This problem can be addressed using reference-based imputation, delta adjustment, and tipping-point analysis. Our new framework tackles this problem analytically. We characterize the process that measures the response regardless of drug discontinuation, Z(t), using its association with two observable processes: time to drug dropout , and the variable representing the response in a hypothetical world without drug discontinuation Y(t). We define the intervention discontinuation effect (IDE) as the unobservable process that quantifies the difference between Y(t) and Z(t) after . We express various well-known imputation rules as forms of the IDE. We model Y using mixed models and with the Royston-Parmar model. We build estimators for the marginal mean of Z given the estimated parameters for Y and T . We demonstrate that this simple estimator building suits all studied rules and provide guidance to extend this methodology. With the proposed framework, we can analytically resolve a broad range of imputation rules and have right-censored treatment discontinuation. This methodology is more efficient and computationally faster than multiple imputation and, unlike Rubin’s variance estimator, presents no standard error over-estimation.","PeriodicalId":51280,"journal":{"name":"Statistics in Biopharmaceutical Research","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2022-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Statistics in Biopharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19466315.2022.2151506","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 1
Abstract
Abstract This article addresses the challenge of implementing the treatment policy strategy when subjects are not followed up after treatment discontinuation. This problem can be addressed using reference-based imputation, delta adjustment, and tipping-point analysis. Our new framework tackles this problem analytically. We characterize the process that measures the response regardless of drug discontinuation, Z(t), using its association with two observable processes: time to drug dropout , and the variable representing the response in a hypothetical world without drug discontinuation Y(t). We define the intervention discontinuation effect (IDE) as the unobservable process that quantifies the difference between Y(t) and Z(t) after . We express various well-known imputation rules as forms of the IDE. We model Y using mixed models and with the Royston-Parmar model. We build estimators for the marginal mean of Z given the estimated parameters for Y and T . We demonstrate that this simple estimator building suits all studied rules and provide guidance to extend this methodology. With the proposed framework, we can analytically resolve a broad range of imputation rules and have right-censored treatment discontinuation. This methodology is more efficient and computationally faster than multiple imputation and, unlike Rubin’s variance estimator, presents no standard error over-estimation.
期刊介绍:
Statistics in Biopharmaceutical Research ( SBR), publishes articles that focus on the needs of researchers and applied statisticians in biopharmaceutical industries; academic biostatisticians from schools of medicine, veterinary medicine, public health, and pharmacy; statisticians and quantitative analysts working in regulatory agencies (e.g., U.S. Food and Drug Administration and its counterpart in other countries); statisticians with an interest in adopting methodology presented in this journal to their own fields; and nonstatisticians with an interest in applying statistical methods to biopharmaceutical problems.
Statistics in Biopharmaceutical Research accepts papers that discuss appropriate statistical methodology and information regarding the use of statistics in all phases of research, development, and practice in the pharmaceutical, biopharmaceutical, device, and diagnostics industries. Articles should focus on the development of novel statistical methods, novel applications of current methods, or the innovative application of statistical principles that can be used by statistical practitioners in these disciplines. Areas of application may include statistical methods for drug discovery, including papers that address issues of multiplicity, sequential trials, adaptive designs, etc.; preclinical and clinical studies; genomics and proteomics; bioassay; biomarkers and surrogate markers; models and analyses of drug history, including pharmacoeconomics, product life cycle, detection of adverse events in clinical studies, and postmarketing risk assessment; regulatory guidelines, including issues of standardization of terminology (e.g., CDISC), tolerance and specification limits related to pharmaceutical practice, and novel methods of drug approval; and detection of adverse events in clinical and toxicological studies. Tutorial articles also are welcome. Articles should include demonstrable evidence of the usefulness of this methodology (presumably by means of an application).
The Editorial Board of SBR intends to ensure that the journal continually provides important, useful, and timely information. To accomplish this, the board strives to attract outstanding articles by seeing that each submission receives a careful, thorough, and prompt review.
Authors can choose to publish gold open access in this journal.